Patients' experiences of medication for anxiety and depression: Effects on working life

Family Practice

Volumn 21, Issue 2, 2004, Pages 204-212

  Haslam, Cheryl ^b   Brown, Sue ^a   Atkinson, Sarah ^a   Haslam, Roger ^a  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anxiety; Compliance; Depression; Patient information; Psychotropic medication

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYCLOPENTHIAZIDE PLUS OXPRENOLOL; DIAZEPAM; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE MALEATE; IMIPRAMINE; LI LIQUID; LITHIUM CARBONATE; LORAZEPAM; MIRTAZAPINE; NEFAZODONE; OXPRENOLOL; PAROXETINE; PINDOLOL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAFEN; TRIPTAFEN M; VENLAFAXINE; VISKALDIX;

ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CONFUSION; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DRUG DEPENDENCE; DRUG INFORMATION; DRUG WITHDRAWAL; EMOTIONAL STRESS; FEMALE; HEADACHE; HEALTH PRACTITIONER; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL EXPERT; MEDICAL RESEARCH; MOTIVATION; NAUSEA; OCCUPATIONAL HEALTH; OCCUPATIONAL SAFETY; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; QUALITATIVE ANALYSIS; SYMPTOMATOLOGY; TREMOR; UNITED KINGDOM; WORKPLACE;

ADOLESCENT; ADULT; ANXIETY DISORDERS; ATTENTION; DEPRESSION; EMPLOYMENT; FAMILY PRACTICE; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL HEALTH SERVICES; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGY, INDUSTRIAL; PSYCHOTROPIC DRUGS; QUALITATIVE RESEARCH; QUALITY OF LIFE; TREATMENT REFUSAL; WORK;

EID: 1842854750     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/cmh218     Document Type: Article

References (15)

1. Potter WZ. Psychotropic medications and work performance. J Occup Med 1990; 32: 355-361.
2. Middleton N, Gunnell D, Whitley E, Dorling D, Frankel S. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med 2001; 23: 262-267.
3. Lawrenson RA, Tyrer F, Newson RB, Farmer RDT. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affective Disord 2000; 59: 149-157.
4. Tilson HH. Medication monitoring in the workplace: toward improving our system of epidemiologic intelligence. J Occup Med 1990; 32: 313-319.
5. Edwards JG. Depression, antidepressants and accidents. Br Med J 1995; 311: 887-888.
6. Demyttenaere K. Compliance and acceptance in antidepressant treatment. Int J Psychiatr Clin Pract 2001; 5 Suppl 1: S29-S35.
7. Lader M. Fortnightly review: treatment of anxiety. Br Med J 1994; 309: 321-324.
8. Knodel J. The design and analysis of focus groups. In: Morgan DL (ed.) Successful Focus Groups: Advancing the State of the Art. Thousand Oaks (CA): Sage Publications; 1993, pp. 35-50.
9. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depression Anxiety 1997; 6: 10-18.
10. MacKay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999; 49: 892-896.
11. Frank E. Enhancing patient outcomes: treatment adherence. J Clin Psychiatr 1997; 58 Suppl 1: 11-14.
12. Graber M, Weckmann M. Pharmaceutical company internet sites as sources of information about antidepressant medications. CNS Drugs 2002; 16: 419-423.
13. Rivas-Vazquez R.A, Carrazana EJ, Rey GJ, Wheeler SD. Selective serotonin reuptake inhibitor discontinuation syndrome: three cases presenting to a neurologic practice. Neurologist 2000; 6: 348-352.
14. Haddad P. Antidepressant discontinuation syndromes. Drug Safety 2001; 24: 183-197.
15. Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitors discontinuation syndrome: a review. Adv Ther 2002; 19: 17-26.